Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Vipoma 2Somatostatinoma 2Rectal Neoplasms 2Insulinoma 2Glucagonoma 2Gastrinoma 2Colorectal Neoplasms 2Carcinoma, Islet Cell 2Thymoma 1Neuroendocrine Tumors 1Neoplasms 1Meningioma 1Drug-Related Side Effects and Adverse Reactions 1Diarrhea 1Colonic Neoplasms 1Breast Neoplasms 1Anus Neoplasms 1Adenoma, Islet Cell 1

Interventions

Fluorouracil 20Leucovorin 18Oxaliplatin 11Irinotecan 10Capecitabine 6Bevacizumab 5Cetuximab 4Levamisole 3Celecoxib 3cediranib 2Watchful Waiting 2Tegafur 2Surveys and Questionnaires 2Psychiatric Rehabilitation 2Folfox protocol 2Counseling 2Cisplatin 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1regorafenib 1pertuzumab 1olaparib 1mercaptoundecahydrododecaborate 1gevokizumab 1eniluracil 1cemiplimab 1brivanib 1alpha-Tocopherol 1Vitamin E 1Uracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Colonic Neoplasms × Octreotide × Clear all
NCT00003057 2023-06-18

Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer

Eastern Cooperative Oncology Group

Phase 3 Completed
500 enrolled
Gastrointestinal

Colonic Neoplasms, Diarrhea, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡